Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

Bispecific antibodies (BsAbs) are emerging as an important novel class of immunotherapeutic agents for the treatment of multiple myeloma (MM), and are set to be more widely used in clinical practice. However, this new class of therapies is associated with a distinct adverse event (AE) profile that i...

Descripción completa

Detalles Bibliográficos
Autores principales: Raje, Noopur, Anderson, Kenneth, Einsele, Hermann, Efebera, Yvonne, Gay, Francesca, Hammond, Sarah P., Lesokhin, Alexander M., Lonial, Sagar, Ludwig, Heinz, Moreau, Philippe, Patel, Krina, Ramasamy, Karthik, Mateos, Maria-Victoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394080/
https://www.ncbi.nlm.nih.gov/pubmed/37528088
http://dx.doi.org/10.1038/s41408-023-00879-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394080/
https://www.ncbi.nlm.nih.gov/pubmed/37528088
http://dx.doi.org/10.1038/s41408-023-00879-7

Ejemplares similares